[14]Han S,Iglay K,Davies MJ,et al.Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis[J].Curr Med Res Opin.2012,28(6):969-77.DOI:10.1185/03007995.2012.684045. [15]Osterberg L,Blaschke T.Adher...
The clinical implications of a new well-tolerated, oral medication which is potentially effi- cacious adjunctive therapy against metastatic PDAC are significant. A future larger randomized clinical trial is warranted to further evaluate the potential efficacy of SGLT2 inhibitor therapy in patients with...
Methods The patient list of a GP surgery was searched for patients coded to have T2DM and ASCVD. Demographics, most recent HbA1c and eGFR, diabetic and cardiology medication were recorded. Search criteria were as follows: Myocardial Infarction, Unstable Angina, Ischaemic Stroke, Haemorrhagic Stroke,...
Diabetes can be treated by medication, and its causes can be avoided or delayed by a healthy diet, physical activity, and regular screening [21]. Traditional treatments of diabetes have side-effects associated with it, that include weight gain, hypoglycemia, increased risk of heart failure, bone...
In each analysis, we selected two groups of AE reports: one listing SGLT2i as suspect or concomitant (active treatment group) and the other listing any other diabetes medication as suspect or concomitant (control treatment group). The group of SGLT2i was composed as follows: "canagliflozin" ...
pathway, involving MAPK pathways, E2F, and others; ii) upregulation of eukaryotic translation, oxidative phosphorylation (OxPhos), TCA cycle, ATP synthesis, mitochondrial function, ribosome biogenesis and immune response-related genes (Fig.3c, see supplementary data file1.xlsxfor complete list). ...
In spite of its sufficient inhibitory effects against SGLTs, phlorizin was ultimately considered to be inappropriate for further development as an antihyperglycemic medication due to some critical drawbacks. First, as described above, phlorizin inhibits both SGLT1 and SGLT2 with low therapeutic ...
glucose output and fatty acid utilization [20]. Previous randomized controlled trials suggest that poor glycemic control at baseline was related to a good response to SGLT-2i [21,22], while renal dysfunction was associated with reduced efficacy of this medication in improving glycemic control [23...
Diabetes in China: Epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 2018, 67, 3–11. [Google Scholar] [CrossRef] [Green Version] Einarson, T.R.; Acs, A.; Ludwig, C.; Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes...
Diabetes in China: Epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 2018, 67, 3–11. [Google Scholar] [CrossRef] [Green Version] Einarson, T.R.; Acs, A.; Ludwig, C.; Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes...